TR201807342T4 - NEDD8 aktive edici enzim inhibitörünün ve hipometile edici ajanın uygulanması. - Google Patents
NEDD8 aktive edici enzim inhibitörünün ve hipometile edici ajanın uygulanması. Download PDFInfo
- Publication number
- TR201807342T4 TR201807342T4 TR2018/07342T TR201807342T TR201807342T4 TR 201807342 T4 TR201807342 T4 TR 201807342T4 TR 2018/07342 T TR2018/07342 T TR 2018/07342T TR 201807342 T TR201807342 T TR 201807342T TR 201807342 T4 TR201807342 T4 TR 201807342T4
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- nae inhibitor
- cancer
- azacitidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555049P | 2011-11-03 | 2011-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201807342T4 true TR201807342T4 (tr) | 2018-06-21 |
Family
ID=48193039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/07342T TR201807342T4 (tr) | 2011-11-03 | 2012-11-02 | NEDD8 aktive edici enzim inhibitörünün ve hipometile edici ajanın uygulanması. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8980850B2 (enExample) |
| EP (1) | EP2773360B1 (enExample) |
| JP (2) | JP6231988B2 (enExample) |
| KR (1) | KR101987861B1 (enExample) |
| CN (1) | CN104245699B (enExample) |
| AU (1) | AU2012321106C1 (enExample) |
| BR (1) | BR112014010699B1 (enExample) |
| CA (1) | CA2854461C (enExample) |
| EA (1) | EA028380B1 (enExample) |
| ES (1) | ES2668272T3 (enExample) |
| GE (2) | GEP20196940B (enExample) |
| HK (1) | HK1201733A1 (enExample) |
| IL (1) | IL232353B (enExample) |
| MA (1) | MA35662B1 (enExample) |
| MX (1) | MX357835B (enExample) |
| MY (1) | MY176125A (enExample) |
| PH (1) | PH12014501001B1 (enExample) |
| PL (1) | PL2773360T3 (enExample) |
| SG (1) | SG11201401895WA (enExample) |
| TN (1) | TN2014000194A1 (enExample) |
| TR (1) | TR201807342T4 (enExample) |
| UA (1) | UA114414C2 (enExample) |
| WO (1) | WO2013067396A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2430026A1 (en) | 2009-05-14 | 2012-03-21 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| MY166889A (en) * | 2011-08-24 | 2018-07-24 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| EP2764866A1 (en) * | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| CN105407973A (zh) | 2013-05-14 | 2016-03-16 | 米伦纽姆医药公司 | Nedd8活化酶抑制剂及化学治疗剂的投与 |
| EA201600134A1 (ru) * | 2013-07-26 | 2016-07-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Воласертиб в комбинации с азацитидином для лечения острого миелоидного лейкоза и миелодиспластического синдрома |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| CN103948590A (zh) * | 2014-05-22 | 2014-07-30 | 中国药科大学 | Nedd8激活酶抑制剂及其医药用途 |
| CA3002029A1 (en) * | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| US11701406B2 (en) | 2017-05-25 | 2023-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases |
| JP2020534331A (ja) * | 2017-09-21 | 2020-11-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用 |
| CA3119781A1 (en) * | 2018-11-20 | 2020-05-28 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| IL323757A (en) | 2019-03-15 | 2025-12-01 | Fulcrum Therapeutics Inc | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
| WO2023242235A1 (en) * | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| CN115007323B (zh) * | 2022-06-17 | 2024-01-23 | 中南大学 | 一种抑制矿物中黄铁矿浮选的方法 |
| US20260023068A1 (en) * | 2022-07-11 | 2026-01-22 | Westlake University | Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| WO2006084281A1 (en) | 2005-02-04 | 2006-08-10 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| HRP20120786T1 (hr) | 2006-02-02 | 2012-11-30 | Millennium Pharmaceuticals, Inc. | Inhibitori aktivirajuä†eg enzima e1 |
| ME02789B (me) * | 2006-08-08 | 2011-06-30 | Millennium Pharm Inc | Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| US20100311683A1 (en) | 2007-11-01 | 2010-12-09 | Beach C L | Cytidine analogs for treatment of myelodysplastic syndromes |
| US20110021517A1 (en) * | 2008-02-26 | 2011-01-27 | Nerviano Medical Sciences S.R.L. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| DK3782612T3 (da) | 2008-05-15 | 2024-01-15 | Celgene Corp | Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf |
| PL2307002T3 (pl) * | 2008-06-09 | 2013-05-31 | Cyclacel Ltd | Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina |
| CN102438588B (zh) * | 2009-03-23 | 2015-04-01 | 埃姆比特生物科学公司 | 使用联合治疗法治疗疾病的方法 |
| EP2430026A1 (en) | 2009-05-14 | 2012-03-21 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| JP2014503597A (ja) | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | シチジンアナログの医薬組成物及びその使用方法 |
| JP6162709B2 (ja) | 2011-11-01 | 2017-07-12 | セルジーン コーポレイション | シチジンアナログの経口製剤を使用して癌を治療する方法 |
-
2012
- 2012-11-02 PL PL12844799T patent/PL2773360T3/pl unknown
- 2012-11-02 ES ES12844799.2T patent/ES2668272T3/es active Active
- 2012-11-02 US US13/667,641 patent/US8980850B2/en active Active
- 2012-11-02 CN CN201280062112.9A patent/CN104245699B/zh active Active
- 2012-11-02 CA CA2854461A patent/CA2854461C/en not_active Expired - Fee Related
- 2012-11-02 PH PH1/2014/501001A patent/PH12014501001B1/en unknown
- 2012-11-02 TR TR2018/07342T patent/TR201807342T4/tr unknown
- 2012-11-02 EA EA201400539A patent/EA028380B1/ru not_active IP Right Cessation
- 2012-11-02 UA UAA201405842A patent/UA114414C2/uk unknown
- 2012-11-02 KR KR1020147014236A patent/KR101987861B1/ko not_active Expired - Fee Related
- 2012-11-02 HK HK15102294.2A patent/HK1201733A1/xx unknown
- 2012-11-02 SG SG11201401895WA patent/SG11201401895WA/en unknown
- 2012-11-02 BR BR112014010699-1A patent/BR112014010699B1/pt not_active IP Right Cessation
- 2012-11-02 WO PCT/US2012/063382 patent/WO2013067396A2/en not_active Ceased
- 2012-11-02 GE GEAP201213483A patent/GEP20196940B/en unknown
- 2012-11-02 GE GEAP201813483A patent/GEP20186940B/en unknown
- 2012-11-02 EP EP12844799.2A patent/EP2773360B1/en active Active
- 2012-11-02 AU AU2012321106A patent/AU2012321106C1/en not_active Ceased
- 2012-11-02 MY MYPI2014001239A patent/MY176125A/en unknown
- 2012-11-02 MX MX2014005323A patent/MX357835B/es active IP Right Grant
- 2012-11-02 JP JP2014540146A patent/JP6231988B2/ja active Active
-
2014
- 2014-04-29 IL IL232353A patent/IL232353B/en active IP Right Grant
- 2014-04-30 TN TNP2014000194A patent/TN2014000194A1/en unknown
- 2014-05-26 MA MA37066A patent/MA35662B1/fr unknown
-
2015
- 2015-01-23 US US14/603,717 patent/US20150366886A1/en not_active Abandoned
-
2017
- 2017-10-20 JP JP2017203560A patent/JP2018009035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2854461C (en) | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent | |
| JP2015511632A (ja) | メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 | |
| Kozloff et al. | An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer | |
| JP2008524225A (ja) | 癌を処置するための治療剤の組合せ | |
| Crinò et al. | Present and future treatment of advanced non–small cell lung cancer | |
| US10786505B2 (en) | Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents | |
| KR20220008870A (ko) | 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물 | |
| US20250064824A1 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
| AU2017330814B2 (en) | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor | |
| US20220071982A1 (en) | Methods and uses for treating cancer |